Overview

* Spero Q3 net loss narrows

* Spero expects cash reserves to fund operations into 2028

Outlook

* Spero expects cash reserves to fund operations into 2028

Result Drivers

* REVENUE DECLINE - Decreased collaboration revenue with GSK and reduced grant revenue led to lower total revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.13

Q3 Net Beat -$7.38 -$22 mln

Income mln (1

Analyst)

Q3 -$7.92

Income mln

From

Operatio

n

Q3 $13.36

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Spero Therapeutics Inc ( SPRO ) is $5.00, about 46.8% above its November 12 closing price of $2.66

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)